Dasatinib
About
About Dasatinib
Dasatinib is an FDA-approved BCR-ABL/Src kinase inhibitor used in chronic myeloid leukemia that has emerged as the most potent senolytic agent identified to date, used in combination with quercetin (D+Q) in clinical longevity trials. The Mayo Clinic's AFFIRM-LITE and similar trials have shown improvements in physical function, biomarkers of senescence, and quality of life in older adults. It represents the leading pharmaceutical approach to eliminating senescent cells.
Science
Mechanism of Action
Selectively induces apoptosis in senescent cells by inhibiting pro-survival kinases (including BCR-ABL, Src, and FAK) that senescent cells depend on for their apoptosis resistance; does not significantly affect non-senescent cells at intermittent low doses.
Dosing
Typical Protocol
100 mg oral once daily for 3 consecutive days, repeated every 2–4 weeks (intermittent senolytic protocol); always combined with quercetin 1,000 mg.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound has completed clinical trials and received formal FDA approval for one or more indications. It can be legally prescribed by licensed physicians, filled at any licensed pharmacy, and may be covered by insurance. Off-label use by physicians is also legal. This is the highest level of regulatory clearance available in the US.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer Dasatinib — with trust scores, legal credentials, and pricing transparency.